Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    LYR-210

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lyra Ditches Sole Rhinosinusitis Asset, Lays Off All Employees
    Lyra Ditches Sole Rhinosinusitis Asset, Lays Off All Employees

    13 Jan 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/lyra-ditches-sole-rhinosinusitis-asset-lays-all-employees

    FIERCE BIOTECH
    13 Jan 2026
    Share Share
    Lyra Therapeutics Provides Corporate Update
    Lyra Therapeutics Provides Corporate Update

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216724/0/en/Lyra-Therapeutics-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Lyra Pharma Reveals LYR-210 Clinical Strategy & ENLIGHTEN 2 Study
    Lyra Pharma Reveals LYR-210 Clinical Strategy & ENLIGHTEN 2 Study

    06 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/06/3161569/0/en/Lyra-Therapeutics-Announces-Clinical-Plan-for-LYR-210-and-Late-Breaking-Oral-Presentation-of-Phase-3-ENLIGHTEN-2-Study.html

    GLOBENEWSWIRE
    06 Oct 2025
    Share Share
    Lyra Reports Topline Phase 3 LYR-210 Chronic Sinusitis Data
    Lyra Reports Topline Phase 3 LYR-210 Chronic Sinusitis Data

    06 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/06/2875729/0/en/Lyra-Therapeutics-Reports-Topline-Results-from-Phase-3-ENLIGHTEN-1-Trial-for-LYR-210-in-Chronic-Rhinosinusitis.html

    GLOBENEWSWIRE
    06 May 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.